ENGLEWOOD, Colo., Sept. 5, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C. Wainwright Global Investment Conference, which is being held on September 11th-13th, 2023.
Zynex's presentation will be held in person and webcast live on September 12th at 3:00 PM ET at the Lotte New York Palace Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Dan Moorhead, CFO, will be available for one-on-one meetings on the 12th and 13th.
To receive additional information, register to attend, or schedule a one-on-one meeting, email the H.C. Wainwright team at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$1.38 |
Daily Volume: | 0 |
Market Cap: | US$41.810M |
October 14, 2025 August 18, 2025 July 31, 2025 June 30, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load